List view / Grid view
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
Researchers create eye neuron network model to study retinal diseases, possible treatment options...
Leading experts of the European Life Sciences Community are engaging under the name BASEL LIFE to establish a bridge between science and business.
Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…
Microdermics has completed its $1 million financing round, which was oversubscribed and received robust global interest.
The human microbiome, comprising of the complex and dynamic microbial communities found on the human body, is essential to our health and observed differences in its composition between patients and healthy people have lead to speculations about the involvement of bacteria in disease development. Such differences have provided evidence towards…
17 March 2016 | By Caroline Richards
Caroline Richards, Editor of Drug Target Review, invites Michael Springer, Associate Professor of Systems Biology, Harvard Medical School to discuss a laboratory study of a yeast model using microfluidic systems...
17 March 2016 | By Merck KGaA
The CellASIC® ONIX2 Microfluidic System for live cell imaging is easy to use and gives researchers precise environmental control over live cells. By providing dynamic control over drug addition, gas, temperature, media and more, this all in one system is the perfect addition to your microscope to enhance your imaging…
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal models in the testing of medicines and in developing personalised treatments for cancer patients.
18 February 2016 | By SELECTBIO
SELECTBIO is delighted to announce Organ-on-a-Chip Europe 2016, which will be held on 5 - 6 April in Cambridge, UK...
Simple Plex assays run on Ella™ enabled simultaneous quantitation of four analytes from eight samples in a disposable cartridge in under an hour...
Microfluidic miniaturisation, or the so-called ‘lab-on-a-chip’ concept, now encroaches on the fields of biology, medicine and pharmacology, and the nature of microfluidic technology (small volumes and high-throughput integration of fluid connections) means that it is outperforming conventional bench work. There has been an incredible need for microfluidic technology in the…
The recent developments in microfluidic technology have provided an effective microreactor platform for the production of a range of pharmaceutically related materials in both nano- and micro-scale. This can be attributed to the unique characteristics that microfluidic-based reactors offer in terms of controllability and uniformity of the material characteristics, compared…
